4.7 Article

Role of RGMc as a Neogenin Ligand in Follicular Development in the Ovary

Journal

BIOMEDICINES
Volume 9, Issue 3, Pages -

Publisher

MDPI
DOI: 10.3390/biomedicines9030280

Keywords

ovary; neogenin; RGMc; follicular development; PGD2; poor ovarian response

Funding

  1. Basic Science Research Program through the National Research Foundation of Korea (NRF) [2018R1D1A1B07050138, 2018R1D1A1B07044016, 2019R1A2C1086882]
  2. National Research Foundation of Korea [2018R1D1A1B07044016, 2018R1D1A1B07050138, 2019R1A2C1086882] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

The neogenin ligand RGMc promotes follicular development in the ovaries via the PGD2 signaling pathway, potentially offering a treatment approach for patients with a POR.
There is currently no cure for infertility in women with a poor ovarian response (POR). Neogenin is reported to be abundantly expressed in the ovary; however, its role in mammalian follicular development is unclear and its ligand and signaling pathway remain uncertain. We systematically investigated the role of neogenin and the ligand repulsive guidance molecule c (RGMc) during follicular development. We treated hyperstimulated mouse ovaries with RGMc and analyzed follicular development. Furthermore, we investigated clusters of up/downregulated genes in RGMc-treated ovaries using whole-transcriptome next-generation sequencing (NGS). In addition, we investigated whether expression of up/downregulated factors identified by NGS was also altered in cumulus cells (CCs) of patients with a POR. The number of oocytes was 40% higher in RGMc-treated ovaries than in control ovaries. NGS data indicated that prostaglandin D2 (PGD2) was involved in the RGMc signaling pathway during follicular development. RGMc treatment significantly elevated the PGD2 level in culture medium of CCs obtained from patients with a POR. Our results demonstrate that RGMc as neogenin ligand promotes follicular development in ovaries via the PGD2 signaling pathway. Therefore, it may be possible to use RGMc for ovarian stimulation in patients with a POR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available